Zynerba Pharmaceuticals — Investor Presentation (January 2018)
39 slides from Zynerba Pharmaceuticals's investor presentation, Jan 30, 2018
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company
Two patent protected compounds: ZYN002 (CBD gel) and ZYN001 (THC pro-drug patch) Focused on high unmet medical needs Fragile X syndrome (FXS): ~71K US patients; no approved products Developmental and epileptic encephalopathies (DEE): ~45K US patients Adult refractory focal epilepsy: ~500K US patient
Slide 3: Expected 2018 Milestones
4 Expected 2018 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting 1Q18 DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 ZYN001 Tourette Syndrome Complete Ph
Slide 4: ZYN002 Cannabidiol (CBD) Gel
First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol (CBD) gel formulated for transdermal delivery CBD binds to multiple receptors and may mediate a number of pathways, including the endocannabinoid pathway Patented formulation increases the delivery of CBD throu
Slide 5: Fragile X Syndrome (FXS) Pivotal-Ready Program
Positive open label Phase 2 data (Sept. 2017): Achieved primary and numerous secondary endpoints with statistical significance vs. baseline Extremely well tolerated U.S. Orphan Drug Designation for use of CBD as a treatment of Fragile X (Feb. 2016) Meeting scheduled with FDA in 1Q2018 to discuss dev
Slide 6: Developmental & Epileptic Encephalopathies (DEE) New Phase 2 Program in 2018
Third party clinical data show impact of CBD on seizures and behavioral issues in children Expect to initiate Phase 2 study in 1H2018 24 week multi-dose study in 48 DEE patients (3-18 years) Two Australian sites Results expected in 2019 7 Developmental & Epileptic Encephalopathies (DEE) New Phase 2
Slide 7: Adult Refractory Focal Epilepsy Phase 2B Anticipated in 2018
Learnings from Phase 2 STAR 1 study and open label STAR 2 extension provide input into Phase 2B trial design STAR 2 data suggest clinically meaningful response with longer term use of ZYN002 Consistent improvements in median seizure rate at three, six and nine months of treatment with ZYN002 Modific
Slide 8: ZYN001 THC Pro-Drug Patch
9 Patent-protected pharmaceutically-produced D-glyceric acid ester-Δ9-tetrahydrocannabinol (THC) in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a normal m
Slide 9: Potential for THC in Tourette Syndrome
10 Potential for THC in Tourette Syndrome (TS) Neurodevelopmental disorder characterized by motor / vocal tics Evident in early childhood ~200K US pts have most severe form (National Institute of Neurological Disorders and Stroke) Up to 1:100 exhibit milder and less complex symptoms Central cannabin
Slide 10: Expected 2018 Milestones
11 Expected 2018 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting 1Q18 DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 ZYN001 Tourette Syndrome Complete P
Slide 11: Zynerba Pharmaceuticals, January 2018
January 2018 Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs
Slide 12: ZYN002 CBD Gel Clinical Program: Fragile X Syndrome
ZYN002 CBD Gel Clinical Program Fragile X Syndrome
Slide 13: Fragile X Syndrome: The Endocannabinoid System is a Critical Pathway
Inherited autism spectrum disorder with symptoms linked to deficiencies in the endocannabinoid system ECs form system of neurotransmitters regulating emotional responses, behavioral reactivity to context, social interaction FMR1 mutation in FXS causes dysregulation of the EC system resulting in sign
Slide 14: Fragile X Syndrome Open Label Phase 2 Trial Design
Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg Daily Screening Titration Weeks 7 to 12 Day 1 to Week 6 Doses of CBD 50 mg, 100 mg, or 250 mg Daily 20 patients enrolled Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD (FAB-C) FAB-C Trial – Peri
Slide 15: Positive FAB-C Open Label Phase 2 Efficacy Data: ADAMS Total Score
ADAMS total score Improvement vs. baseline (N=20) Changes in Anxiety, Depression and Mood 46% (p<0.0001) ADAMS subscales Improvement vs. baseline (N=20) General Anxiety 54% (p<0.0001) Social Avoidance 53% (p<0.0002) Compulsive Behavior 50% (p=0.0262) Manic/Hyperactive Behavior 35% (p=0.0003) Depress
Slide 16: Positive FAB-C Open Label Phase 2 Efficacy Data: ABC-FXS
17 ABC-FXS subscale Improvement vs. baseline (N=20) Stereotypy: "Repetitive Movements" 59% (p=0.0006) Social Avoidance: "Seeks Isolation" 55% (p=0.0005) Socially Unresponsive/Lethargic: "Does Not Pay Attention" 53% (p=0.0034) Inappropriate Speech: "Repeats Words or Phrases" 43% (p=0.0018) Irritabili
Slide 17: ADAMS Subscales Week 12: Percent Improvement vs. 3rd Party Data
18 Manic/hyperactive Behavior Depressed Mood Social Avoidance General Anxiety Compulsive Behavior Baseline: 9.4 Baseline: 8.1 8.7 Baseline: 2.8 Baseline: 3.0 3.1 Baseline: 10.2 Baseline: 6.9 7.5 Baseline: 10.0 Baseline: 7.9 8.3 Baseline: 2.8 Baseline: 3.0 3.4 * Ligsay, A., Van Dijck, A., Nguyen, D.
Slide 18: ABC-FXS Subscales Week 12: Percent Improvement vs. 3rd Party Data
19 Irritability Temper Tantrums Hyperactivity Disrupts Group Activities Socially Unresponsive / Lethargic Does Not Pay attention Social Avoidance Seeks Isolation Stereotypy Repetitive Movements Baseline: 18.2 Baseline: 18.9 19.6 Baseline: 14.5 Baseline: 13.9 13.9 Baseline: 8.7 Baseline: 6.6 6.9 Base
Slide 19: Positive FAB-C Open Label Phase 2 Safety Data
20 Very well tolerated, consistent with previously reported clinical data Two sibling patients discontinued due to worsening of pre-existing eczema Four other patients experienced an AE; no SAEs No drug-related GI events No THC was detected in the plasma 13 patients continued into open label extensi
Slide 20: Fragile X Syndrome Pivotal Phase 2/3 Study Proposed Trial Design
Period 1 Period 2 Up to 12 Months Fragile X Syndrome Pivotal Phase 2/3 Study Proposed Trial Design* ZYN002 Twelve weeks, randomized (1:1) double-blind, placebo-controlled Screening 21 Target: 132 patients Placebo Run-in 2 weeks Randomization Day 1 Treatment 12 weeks ZYN002 100 mg daily (N=66) Placeb
Slide 21: ZYN002 in Fragile X Syndrome Next Steps
22 Meeting scheduled with FDA in 1Q2018 to discuss development strategy including clinical pivotal program Goal to begin pivotal Phase 2/3 program in pediatric and adolescent patients with FXS mid-year 2018 Data expected in 2019 Assessing opportunity to present / publish full data set as soon as pos
Slide 22: ZYN002 CBD Gel Clinical Program: Developmental Epileptic Encephalopathies (DEE)
ZYN002 CBD Gel Clinical Program Developmental Epileptic Encephalopathies (DEE)
Slide 23: Developmental and Epileptic Encephalopathies
Category of rare and ultra-rare severe brain disorders that manifest with seizures or EEG abnormalities that can directly worsen cognition or behavior Often progressive; highly resistant to treatment Treatment of seizures or EEG abnormalities expected to improve the cognitive or behavioral deficits
Slide 24: DEE Open Label Phase 2 Study Proposed Trial Design
Period 1 Period 2 DEE Open Label Phase 2 Study Proposed Trial Design* ZYN002 25 *Note: Subject to change due to further regulatory, clinical and other considerations. Weight based dosing from 250 to 780 mg daily Screening Titration 24 weeks Two weeks Up to 12 Months 2-3 week taper period Extension T
Slide 25: ZYN002 CBD Gel Clinical Program: Adult Refractory Focal Epilepsy
ZYN002 CBD Gel Clinical Program Adult Refractory Focal Epilepsy
Slide 26: Adult Refractory Focal Epilepsy Phase 2B Anticipated in 2018
Learnings from Phase 2 STAR 1 study and open label STAR 2 extension provide input into Phase 2B trial design STAR 2 data suggest clinically meaningful response with longer term use of ZYN002 Consistent improvements in median seizure rate at three, six and nine months of treatment with ZYN002 Modific
Slide 27: Epilepsy Phase 2 Clinical Study Trial Design
ZYN002 High-Dose CBD 195 mg BID ZYN002 Low-Dose CBD 97.5 mg BID Placebo Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy ZYN002 CBD 195 mg BID STAR 2 Trial STAR 1 Trial Dose can be adjusted to: BID for 18 months BID for 12 we
Slide 28: STAR 1 Demographics and Baseline Characteristics
Epilepsy Phase 2 Clinical Study Demographics and Baseline Characteristics ZYN002 STAR 1 patients Placebo 195 mg ZYN002 390 mg ZYN002 Total Pts Randomized 63 63 62 188 Sex 43% male 57% female 51% male 49% female 42% male 58% female 45% male 55% female Pts Analyzed for efficacy 63 62 61 186 Pts comple
Slide 29: Epilepsy Phase 2 Clinical Study STAR 1 and STAR 2 Results
Epilepsy Phase 2 Clinical Study STAR 1 and STAR 2 Results Company believes study missed primary endpoint due to bimodal distribution of placebo patient responses : >50% reductions in focal seizures in ~¼ of placebo patients 13 of these 15 patients were female Strong separation from placebo seen at >
Slide 30: New Data Presented at AES: STAR 1 and STAR 2 Efficacy Data
New Data Presented at AES STAR 1 and STAR 2 Efficacy Data 31 -8.70 N=63 -18.42 N=62 -14.03 N=61 -13.40 N=59 -32.68 N=55 -30.04 N=55 -26.53 N=24 -65.23 N=21 -48.45 N=18 STAR 1 STAR 2 Week 12 Month 6 Month 3 Median Percent Change in Seizure Rates Placebo ZYN002 195 mg ZYN002 390 mg Placebo (STAR 1) –
Slide 31: Consistent Results at Various Timeframes: Three Months on ZYN002
32 -18.4 N=62 -14.0 N=61 -13.4 N=59 -32.68 N=55 -30.04 N=55 -26.53 N=24 -65.23 N=21 -48.45 N=18 195 mg – 390 mg Placebo – 390 mg 390 mg – 390 mg Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-August 2017 and in patients who
Slide 32: Consistent Results at Various Timeframes: Six Months on ZYN002
33 -18.4 N=62 -14.0 N=61 -13.4 N=59 -32.7 N=55 -30.0 N=55 -26.5 N=24 -65.23 N=21 -48.45 N=18 195 mg – 390 mg Placebo – 390 mg 390 mg – 390 mg Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-August 2017 and in patients who re
Slide 33: Consistent Results at Various Timeframes: Nine Months on ZYN002
34 -18.4 N=62 -14.0 N=61 -13.4 N=59 -32.7 N=55 -30.0 N=55 -26.5 N=24 -65.2 N=21 -48.5 N=18 195 mg – 390 mg Placebo – 390 mg 390 mg – 390 mg Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-August 2017 and in patients who repo
Slide 34: Proposed Phase 2b Study: Adult Refractory Focal Epilepsy
~300 patient double-blind placebo controlled study To be conducted in US, Australia and New Zealand Primary endpoint: reduction from baseline in focal seizures 1:1:1 ratio (195 mg: 780 mg: placebo) 35 Learnings from STAR 1 and STAR 2 experience include: Stratified randomization by baseline seizure r
Slide 35: Financial Strength
Cash and cash equivalent position of $66.3 million (September 30, 2017) Additional $3.0 million in net proceeds from shares sold in September and October 2017 under our ATM program Recorded in the fourth quarter of 2017 Well capitalized, expect cash to fund operations well into 2019 36 Financial Str
Slide 36: Scientific advisors and clinical investigators
Randi J. Hagerman, MD Medical Director, UC Davis MIND Institute, Distinguished Professor, Endowed Chair in Fragile X Research, Department of Pediatrics, UC Davis School of Medicine Steven J. Siegel, MD, PhD Chair, Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University
Slide 37: Investor Relations
38 484.581.7505 investorrelations@zynerba.com www.zynerba.com @ZynerbaPharma Zynerba Zynerba Investor Contact Will Roberts, VP, Investor Relations and Corporate Communications 484.581.7489 NASDAQ: ZYNE Analyst Coverage* Piper Jaffray: Charles C. Duncan, PhD Cantor Fitzgerald: Elemer Piros, PhD Canac
Slide 38: Zynerba Pharmaceuticals, January 2018
January 2018 Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs
Slide 39: Zynerba
— ynerba’ to the development and ‘cialization of innovative transdermal utically-produced cannabinoid treatments for rare and near-rare 3 neuropsychiatric conditions in patients with high unmet mi 11 needs January 2018 ynerba
Zynerba Pharmaceuticals — Investor Presentation (January 2018) on 6ix